Instrument Inactif

Communiqués Opexa Therapeutics Inc Nasdaq

Actions

US68372T3014

Recherche biotechnologique et médicale

Communiqués

02/11/23	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals	AQ
10/10/23	ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER	BU
06/09/23	ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER	BU
31/08/23	Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product	AQ
30/08/23	Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe	AQ
14/08/23	Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update	AQ
26/06/23	Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and Founder	AQ
07/06/23	Acer Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	PU
15/05/23	Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update	AQ
04/05/23	ACER THERAPEUTICS INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
01/05/23	ACER THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
01/05/23	Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of Schedule	AQ
27/04/23	Acer Therapeutics : Sales Agreement - Form 8-K	PU
27/04/23	ACER THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
27/03/23	ACER THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
27/03/23	ACER THERAPEUTICS INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
27/03/23	Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update	AQ
22/03/23	ACER THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
22/03/23	Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes	AQ
22/03/23	Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	AQ
17/03/23	ACER THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
17/03/23	Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial	AQ
15/03/23	ACER THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
15/03/23	Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides OLPRUVA™ Program Update	AQ
13/02/23	ACER THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ